PARIS, October, 10 2017 – Bryan, Garnier & Co, the leading pan-European Investment Bank focusing on growth companies, is delighted to welcome Jamila El Bougrini and Marion Levi to its Equity Research Healthcare team in Paris, increasing its size and scope with the objective of expanding the stocks covered in the sector.
Jamila and Marion will join the Biotech segment of the Healthcare space where the bank is increasing its presence since it is the main source of innovation in the sector. The intent is not only to cover a greater number of listed companies but also to build and develop expertise in new emerging fields such as CAR-T therapies, mRNA-based technologies or microbiome. This will help investors navigate across this buoyant sector, learn fast about new technologies and try capture the greatest possible part of the value to be obtained as early as possible i.e. sometimes when companies are not even public.
Jamila has a PhD in Cellular and Molecular Biology from Paris-Orsay University and an MBA in International Management from Paris-Dauphine University. Prior to joining Bryan Garnier, she worked in the field of research funding, especially in the oncology area within the ARC Foundation for Cancer Research as a Scientific Officer during four years. Then, Jamila worked in a French boutique dedicated to Biotech and Medtech companies, where she acted as a Life Science Analyst for two years. She had the opportunity to participate in a variety of operations such as IPOs, capital increases and strategic advice based on business and asset valuation.
Marion has an Engineering degree in Industrial Biology, a Master of Science in Stem cells and Regenerative Medicine (Newcastle University, UK) and a Specialized Master in Biopharmaceutical Management from the ESCP Europe business school (Paris, France). Before joining Bryan, Garnier & Co, she worked in a French dermo-cosmetic company in the R&D department, where she was in charge of scientific studies. She participated in numerous projects, such as the establishment of new laboratory protocols to evaluate dermo-cosmetic products from several brands.
Eric Le Berrigaud, Managing Partner, Paris, comments: "We are clearly strengthening our position with the addition of Jamila and Marion to the team. We achieve the triple objective of capturing the deep value of the healthcare sector, expanding our coverage capacity and accurately looking into the technical aspects of it – all for the greater benefit of our clients”.
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European, full service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Media & Telecoms, Healthcare, Smart Industries & Energy, Consumer, Brands & Retail and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich and New York. The firm is a member of the London Stock Exchange and Euronext.